Sundt AS
VC Fund
Sundt AS is a VC fund focused on Biotechnology and Big Data. Privately owned investment company.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Sundt AS invests in
Stages Sundt AS invests in
Countries Sundt AS invests in
Investment Focus
Industry
- Biotechnology 2 (67%)
- Big Data 1 (33%)
- Chemical 1 (33%)
- Software 1 (33%)
- Analytics 1 (33%)
Stage
- Series A 1 (33%)
- Post-IPO Equity 1 (33%)
- Venture - Series Unknown 1 (33%)
Country
- Norway 2 (67%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EXACT Therapeutics
|
EXACT Therapeutics is a clinical-stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range oftherapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. | $13.1M / Post-IPO Equity / Dec 03, 2024 | |
Oncoinvent
|
Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns. | $29.2M / Venture - Series Unknown / Jun 29, 2021 | |
Arundo Analytics
|
With offices in Oslo, Houston, and Silicon Valley, Arundo Analytics provides cloud-based and edge-enabled software for the deployment and management of enterprise-scale industrial data science solutions. Arundo's software allows industrial companies and other organizations to increase revenue, reduce costs and mitigate risks through machinelearning and other analytical solutions that connect industrial data to advanced models and connect model insights to business decisions. In 2016, Arundo graduated from Stanford University’s StartX accelerator program and subsequently received investment from the Stanford-StartX Fund. In 2017, Arundo was named to the MIT STEX25 by the Massachusetts Institute of Technology Startup Exchange (MIT STEX). MIT STEX25 recognizes select companies from a pool of more than 1,000 MIT-connected startups as being particularly well-suited for industry collaboration based on technical and commercial success. For more information, please visit www.arundo.com, or follow Arundo Analytics on Twitter @arundoanalytics. | $25M / Series A / Jan 25, 2018 |
Co-Investors
Arctic Fund Management
1 deal together
BaseN
1 deal together
Hadean Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sundt AS invest in?
Sundt AS invests primarily in Biotechnology, Big Data and Chemical startups, most often at Series A and Post-IPO Equity stage. Most of the 3 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Sundt AS last invest?
The most recent investment recorded for Sundt AS closed in Dec 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
